Q3-FY26 · Sanjiv Jain
Our healthy operating performance was characterized by strong execution across multiple key segments. CDMO registered a healthy topline growth of more than 16% driven by strong volumes.
AKUMSDRUGSPHARMACEUTICAL / language trends
Read confidence between the lines.
Akums Drugs & · tone and specificity signals across the available quarters.
Research layer active
Language signals
What changed in management language.
tracked
Q3-FY26 · Sahil Maheshwari
So the recovery has come both in terms of margins as well as in terms of topline to us and the recovery looks stable as of now.
Q3-FY26 · Sanjiv Jain
We continue to work towards reducing losses in the trade generic and API segment by way of portfolio rationalization and tighter control over overheads.
Q4-FY26 · Sanjay Jain
We have visibility for 45 to 60 days of our revenue book. So what we said is in Q1 Q2 as we can see we expect a double digit volume growth.
Q4-FY26 · Sanjay Jain
This is an established brand already marketed with predictable volumes being sold in the European market. So once we start, we will have almost a 35 million euro on a mat basis.
Q4-FY26 · Sanjay Jain
We are still evaluating when to enter at which stage to enter given the pricing still remains very volatile.